동아메디칼

비상장계속사업자

DONG-A MEDICAL CO LTD

김진태

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

동아메디칼

Business Reg. No. 6048128487 · CEO 김진태

I.Investment Overview

Target동아메디칼 (6048128487)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명동아메디칼
영문명DONG-A MEDICAL CO LTD
대표자김진태
사업자등록번호6048128487
법인등록번호1801110185199
설립일1995.07.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW223.52021231.92022229.62023218.62024213.12025
영업이익100M KRW17.220217.520226.520239.320242.72025
순이익100M KRW7.520228.8202311.220243.12025
Item20252024202320222021
자산총계205.8억원200.5억원201.5억원181억원
부채총계106억원115억원124.8억원111.7억원
자본총계99.8억원85.5억원76.7억원69.2억원
매출액213.1억원218.6억원229.6억원231.9억원223.5억원
영업이익2.7억원9.3억원6.5억원7.5억원17.2억원
순이익3.1억원11.2억원8.8억원7.5억원

VI.Financial Ratios

FY2025 basis

1.27%

영업이익률

1.44%

순이익률

1.5%

ROA

3.08%

ROE

106.27%

부채비율

48.48%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

동아메디칼 투심보고서 | Alpha Lenz